Pharmacological treatment of patients with schizophrenia and substance abuse disorders

Addictive Disorders and their Treatment

Volumn 4, Issue 4, 2005, Pages 127-137

  Tsuang, John ^a   Fong, Timothy W ^b   Pi, Edmond ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Effective pharmacological treatment of dual diagnosis patients; Pharmacology of substance abuse; Schizophrenia and substance abuse

Indexed keywords

ACAMPROSATE; ANTACID AGENT; ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DISULFIRAM; ECOPIPAM; GABAPENTIN; HALOPERIDOL; LITHIUM; METHADONE; MUSCLE RELAXANT AGENT; NALTREXONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ALCOHOL ABUSE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; DETOXIFICATION; DRUG EFFICACY; DYSPHORIA; EXTRAPYRAMIDAL SYNDROME; FLUSHING; HUMAN; MENTAL PATIENT; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; SIDE EFFECT; SMOKING; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VOMITING; WITHDRAWAL SYNDROME;

EID: 27944461757     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000179235.45424.ca     Document Type: Article

References (126)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
2. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis. 1987;175:641-652.
3. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol. 1992;60:845-856.
4. Soyka M, Albus M, Finelli A, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci. 1993;242:362-372.
5. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis. 1989;177:408-414.
6. Owen RR, Fischer EP, Booth BM. Medication compliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47:853-858.
7. Shaner A, Eckman TA, Roberts LJ, et al. Disability income, cocaine use, and repeated hospitalization among schizophrenic cocaine abusers - a government-sponsored revolving door? N Engl J Med. 1995;333:777-783.
8. Haywood TW, Kravitz HM, Grossman LS. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995;152:856-861.
9. Swofford CD, Kasckow JW, Scheller GG. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res. 1996;20:145-151.
10. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35:S93-100.
11. Green AI, Canuso CM, Brenner MJ, et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am. 2003;26:115-139.
12. Dickey B, Normand SL, Weiss RD, et al. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002;53:861-867.
13. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Bull. 2002;54:253-264.
14. Ries R, Mullen M, Cox G. Symptom severity and utilization of treatment resources among dually diagnosed inpatients. Hosp Community Psychiatry. 1994;45:562-568.
15. Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health. 1996;86:973-977.
16. Khantzian EJ. A self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142:1259-1264.
17. Green AI, Saloman MS, Brenner MJ, et al. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets - CNS & Neurol Disord. 2002;1:129-139.
18. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav. 1998;23:717-734.
19. Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry. 1991;148:224-230.
20. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol. 1992;60:845-856.
21. Lysaker P, Bell M, Beam-Goulet J, et al. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis. 1994;182:109-112.
22. Lieberman JA, Kane MJ, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987;91:415-433.
23. Janowsky DS, Davis JM. Methylphenidate, dextroamphetamine, and levamfetamine: effects on schizophrenic patients. Arch Gen Psychiatry. 1976;33:304-308.
24. Richard ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry. 1985;46:79-83.
25. Potvin S, Stip E, Roy J. Schizophrenia and addiction: an evaluation of the self medication hypothesis. Encephale. 2003;29:193-203.
26. Drake RE, Mueser KT. Managing comorbid schizophrenia and substance abuse. Curr Psychiatry Rep. 2001;3:418-422.
27. Lehman AF, Dixon L, Hoch JS, et al. Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. Br J Psychiatry. 1999;174:346-352.
28. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis demographic characteristics, clinical features, and family history. Arch Gen Psychiatry. 1982;39:141-147.
29. Tsuang M, Lyons M, Tsuang J, et al. Relationship of drug abuse to psychotic symptoms. Symposium presentation at the American Psychiatric Association Annual Meeting, 1997.
30. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13:177-184.
31. Goldstein M, Deutch AY. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 1992;6:2413-2421.
32. Chambers AC, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71-83.
33. Keverne EB. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res Bull. 1999;48:467-473.
34. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull. 2000;26:105-118.
35. Bellack AS, Gearon JS. Substance abuse treatment for people with schizophrenia. Addict Behav. 1998;23:749-766.
36. Bellack AS, Diclemente C. Treating substance abuse among patients with schizophrenia. Psychiatr Serv. 1999;50:75-80.
37. Glazer WM, Morgenstern H. Predictors of occurrence, severity, and course of TD in an outpatient population. J Clin Psychopharmacol. 1988;8:10S-16S.
38. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse. 1990;16:57-66.
39. Zaretsky A, Rector NA, Seeman MV, et al. Current cannabis use and tardive dyskinesia. Schizophr Res. 1993;11:3-8.
40. Bailey L, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull. 1997;22:177-181.
41. Dixon L, Weiden PJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry. 1992;33:121-122.
42. Siegfried SI, Fleishchacker W, Lieberman JA. Pharmacological treatment of schizophrenia. In: Lieberman JA, Murray RM, eds. Comprehensive Care of Schizophrenia. London: Martin Dunitz; 2001:59-94.
43. Harvey PD, Keefe RE. Cognition and the new antipsychotics. International Journal of Advances in Schizophrenia and Brain Research. 1998;1:2-8.
44. Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60:81-85.
45. Ziedonis D, D'Avanzo K. Schizophrenia and substance abuse. In: Kranzler HR, Rounsaville BJ, eds. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York: Marcel Dekker, Inc.; 1998:427-459.
46. Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat. 1998;15:113-116.
47. Soyka M. Dual diagnosis in patients with schizophrenia: issues in pharmacological treatment. CNS Drugs. 1996;5:414-425.
48. Kosten TA, Nestler EJ. Clozapine attenuates cocaine conditioned place preference. Life Sci. 1994;55:PL9-14.
49. Roberts DCS, Vickers G. Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioral screen for antipsychotic activity. Psychopharmacology (Berl). 1984;82:135-139.
50. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine (letter). Am J Psychiatry. 1995;152:959.
51. McEvoy J, Freudenreich O, McGlee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995;37:550-552.
52. Albanese MJ, Khantzian EJ, Murphy SI. Decreased substance use in chronically psychotic patients treated with clozapine (letter). Am J Psychiatry. 1994;151:780-781.
53. Tsuang J, Eckman T, Shaner A, et al. Clozapine for substance abusing schizophrenic patients. Am J Psychiatry. 1999;156:1119-1120.
54. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis. 1994;182:591-592.
55. Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry. 1998;59(Suppl 3):26-30.
56. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441-449.
57. Buckley PF, Thompson P, Way L, et al. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry. 1994;151:385-389.
58. Smelson DA, Roy A, Roy M. Risperidone and neuropsychological test performance in cocaine-withdrawn patients. Can J Psychiatry. 1997;42:431.
59. Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002;47:671-675.
60. Tsuang JW, Eckman T, Marder S, et al. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol. 2002;22:629-630.
61. Newton TF, Ling W, Kalechstein AD, et al. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res. 2001;102:227-233.
62. Fong TW, Newton TF, Kalechstein AD, et al. Risperidone blunts cocaine-induced craving for cocaine (abstract). Drug Alcohol Depend. 2001;63:S48.
63. Sakhi S, Newton TT, Kalechstein AD, et al. Risperidone reduces euphoric effects of cocaine (abstract). Drug Alcohol Depend. 2001;63:S137.
64. Roy A, Roy M, Smelson D. Risperidone, ERG, and cocaine craving (letter). Am J Addict. 1998;7:90.
65. Albanese M. Risperidone in substance abusers with bipolar disorder. Abstract presented at: 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); San Juan, Puerto Rico; December 10-14, 2000.
66. Albanese MJ. Safety and efficacy of risperidone in substance abusers with psychosis. Am J Addict. 2001;10:190-191.
67. Huang CC. Risperdal reduces alcohol use in dual disabled schizophrenic patients. Eur Neuropsychopharmacol. 1996;6:43.
68. Grabowski J, Rhoades H, Silverman P, et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol. 2000;20:305-310.
69. Berk S, Brook F, Nur M. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. International Journal of Psychiatry in Clinical Practice. 2000;4:139-142.
70. Wachtel SR, Ortengren A, de Wit H. The effects of acute haloperidol on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend. 2002;68:23-33.
71. Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry. 1998;59(Suppl 12):46-52.
72. Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry. 1997;58(Suppl 10):18-21.
73. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment refractory - schizophrenic patients with a history of substance abuse. Schizophr Res. 1998;33:95-101.
74. Littrell KH, Peabody CD, Littrell SH. Olanzapine: a new atypical antipsychotic. J Psychosoc Nurs Ment Health Serv. 1996;34:41-46.
75. Longo LP. Olanzapine for cocaine craving and relapse prevention in 2 patients. J Clin Psychiatry. 2002;63:595-596.
76. Tsuang J, Marder SR, Han A, et al. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002;63:1180-1181.
77. Cruz HA, Haider S. Effectiveness of quetiapine in Orlando, FL, patients with dual diagnosis (poster). Presented at the: APA Institute on Psychiatr Serv, 2002.
78. Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord. 2002;4:406-411.
79. Brown ES, Nejtek BA, Perantie DC. Neuroleptics and quetiapine in psychiatric illnesses with comorbid stimulant abuse (poster). Presented at: the Society of Biological Psychiatry Annual Meeting, May 16-18, 2002; Philadelphia, PA.
80. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Nueropsychopharmacology. 2003;28:182-192.
81. Casey DE. Atypical antipsychotics: enhancing healthy outcomes. Arch Psychiatr Nurs. 2002;16(Suppl 1):S12-S19.
82. Casey DE. Clinical trial design issues in schizophrenic discussion 21-22 research. J Clin Psychiatry. 2001;62(Suppl 9):17-20.
83. Ziedonis DM, Kosten TR. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J Psychoactive Drugs. 1991;23:417-425.
84. Kosten TR. Pharmacotherapeutic interventions for cocaine abuse matching patients to treatment. J Nerv Ment Dis. 1989;177:379-389.
85. Ziedonis D, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull. 1992;28:309-314.
86. Soyka M, Sand P. Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry. 1995;28:64-65.
87. Schilkrut R, Cabrera J, Morales E, et al. Neuroleptics in the treatment of drug dependence in schizophrenics: a study with flupenthixol decanoate (abstract no. 33.01.50). Psychopharmacology (Berl). 1988;96(Suppl):342.
88. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry. 1992;53:426-433.
89. Davis M, Metalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs. 1994;47:741-773.
90. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125-1132.
91. Bickel WK, Stitzer ML, Bigelow GE, et al. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43:72-78.
92. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35:501-516.
93. Welsh C, Liberto J. The use of medication for relapse prevention in substance dependence disorders. J Psychiatr Pract. 2001;7:15-31.
94. Kinsbury SJ, Salzman C. Disulfiram in the treatment of alcoholic patients with schizophrenia. Hosp Community Psychiatry. 1990;41:133-134.
95. O'Malley S, Adamse M, Heaton RK, et al. Neuropsychological impairment in chronic cocaine abusers. Am J Drug Alcohol Abuse. 1992;18:131-144.
96. Volpicelli JT, Alterman AI, Hayashida M, et al. Naltrexone in treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
97. Dougherty RJ. Naltrexone in the treatment of alcohol dependent dual-diagnosed patients (abstract). J Addict Dis. 1997;16:107.
98. Maxwell S, Shinderman MS. Naltrexone in the treatment of dually-diagnosed patients (abstract). J Addict Dis. 1997;16:107.
99. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
100. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Arch Gen Psychiatry. 1996;53:673-680.
101. Johnson BA, Ait-Daoud N, Akhtar FZ, et al. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61:905-912.
102. Millson RC, Owen JA, Lorberg GW, et al. Topiramate for refractory schizophrenia. Am J Psychiatry. 2002;159:675.
103. Zullino DF, Khazaal Y, Hattenschwiler J, et al. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today (Barc). 2004;40:603-619.
104. Rao S, Ziedonis D, Kosten T. The pharmacotherapy of cocaine dependence. Psychiatr Ann. 1995;25:363-368.
105. Wilkins JN. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull. 1997;23:215-228.
106. Siris S. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull. 1990;16:111-122.
107. Seibyl J.Personal communication on mazindol study, 1993.
108. Johnson R. Mazindol Augmentation of Neuroleptics in Cocaine Abusers: 1993 New Research Program and Abstracts. Washington, DC: American Psychiatric Association; 1992:92.
109. Ritz MC, Lamb RJ, Goldberg SR, et al. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219-1223.
110. George TP, Chawarski MC, Pakes J, et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry. 2000;47:1080-1086.
111. McCane-Katz EF, Kosten TR, Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 1998;52:27-39.
112. McCane-Katz EF, Kosten TR, Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol Psychiatry. 1998;43:540-543.
113. Schein JR. Cigarette smoking and clinically significant drug interactions. Ann Pharmacother. 1995;29:1139-1148.
114. Shimoda K, Someya T, Morita S, et al. Lower plasma levels of haloperidol in smoking than in non-smoking schizophrenic patients. Ther Drug Monit. 1999;21:293-296.
115. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot-smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23:247-254.
116. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry. 1996;57(Suppl):12-25.
117. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999;60(Suppl 10):20-30.
118. Hasegawa M, Gutierrez-Esteinou R, Way L, et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol. 1993;6:383-390.
119. De Leon J, Dadvand M, Canuso C, et al. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry. 1995;152:453-455.
120. Salokangas RK, Saarijarvi S, Taiminen T, et al. Effect of smoking on neuroleptics in schizophrenia. Schizophr Res. 1997;23:55-60.
121. American Psychiatric Association. APA practice guideline for the treatment of patients with nicotine dependence. Washington, DC. Am J Psychiatry. 1996.
122. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23:247-254.
123. Addington J. Group treatment for smoking cessation among persons with schizophrenia. Psychiatr Serv. 1998;49:925-928.
124. Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res. 1996;22:133-141.
125. George TP, Sernyak MJ, Ziedonis DM, et al. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 1995;56:344-346.
126. Oyewumi LK. Smoking cessation and clozapine side effects. Can J Psychiatry. 1998;43:748.